Novel pharmacological treatments for heart failure.
Pharmacological therapies remain the primary strategy for treating patients with acute and chronic heart failure. Several novel neurohormonal antagonists, inotropic agents, immune modulators, and metabolic and replacement therapies are currently in development to meet the demands of an increasing number of patients with heart failure. The success in drug development in this field will require a better understanding of the effects of heart failure on drug dosing, better integration of novel and existing drug therapies, the development of more reliable surrogate markers to effectively tailor medical therapy to individual needs and the ability to detect and treat patients at risk before the onset of heart failure.
Tang
W H Wilson
WH
Kaufman Center for Heart Failure, Cleveland Clinic Foundation, CLeveland, OH 44195, USA. tangw@ccf.org
Francis
Gary S
GS
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D002316:Cardiotonic Agents / Q000627:therapeutic use; D002317:Cardiovascular Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D015195:Drug Design; D006333:Heart Failure / Q000188:drug therapy*; D020249:Hormone Replacement Therapy; D006801:Humans; D018377:Neurotransmitter Agents / Q000037:antagonists & inhibitors; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D000893:Anti-Inflammatory Agents; D002316:Cardiotonic Agents; D002317:Cardiovascular Agents; D018377:Neurotransmitter Agents; D010726:Phosphodiesterase Inhibitors